Yahoo
OTC Markets OTCPK - Delayed Quote USD

Sumitomo Pharma Co., Ltd. (DNPUF)

11.91 0.00 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for DNPUF
  • Previous Close 11.91
  • Open 10.50
  • Bid 10.49 x 30000
  • Ask 14.36 x 10000
  • Day's Range 10.50 - 10.50
  • 52 Week Range 8.41 - 19.20
  • Volume 118
  • Avg. Volume 56
  • Market Cap (intraday) 5.343B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 7.54
  • EPS (TTM) 1.58
  • Earnings Date (est.) Jan 29, 2027
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Mar 30, 2027
  • 1y Target Est --

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

www.sumitomo-pharma.com

--

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

DNPUF
17.06%
Nikkei 225 (^N225)
25.73%

1-Year Return

DNPUF
8.37%
Nikkei 225 (^N225)
23.31%

3-Year Return

DNPUF
272.19%
Nikkei 225 (^N225)
106.18%

5-Year Return

DNPUF
26.49%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 137B
Earnings 21.24B
Profit Margin 15.50%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
50B
100B
0.0%
5.0%
10.0%
15.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.39%

  • Return on Assets (ttm)

    -0.14%

  • Return on Equity (ttm)

    13.27%

  • Revenue (ttm)

    492.66B

  • Net Income Avi to Common (ttm)

    46.24B

  • Diluted EPS (ttm)

    1.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    77.76B

  • Total Debt/Equity (mrq)

    32.40%

  • Levered Free Cash Flow (ttm)

    16.9B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: